Table 2 Comparison between asymptomatic CRE carriers and non-carriers who developed BSI in neutropenic children
Factors | CRE carriers (n = 19) | Non-carriers (n = 12) | P value |
|---|---|---|---|
Male, no. (%) | 8 (42.1) | 7 (58.3) | 0.379 |
Age (years), median (range) | 8 (1–13) | 4 (1–13) | 0.460 |
CRE strains, no. (%) | Â | Â | Â |
 Escherichia coli | 13 (68.4) | 3 (25.0) | 0.050 |
 Klebsiella pheuminiae | 3 (15.8) | 6 (50.0) | |
 Enterobacter cloacae | 3 (15.8) | 3 (25.0) | |
Prior antibiotic exposure, no. (%) | Â | Â | Â |
  Cephalosporin | 15 (78.9) | 11 (91.7) | 0.348 |
 Carbapenem | 9 (43.4) | 6 (50.0) | 0.886 |
  Glycopeptides | 7 (36.8) | 4 (33.3)3 | 0.842 |
  Fluoroquinolone | 2 (10.5) | 1 (8.3) | 0.841 |
Underlying diagnosis | Â | Â | Â |
 Acute leukemia | 14 (73.7) | 10 (83.3) | 0.531 |
 Severe aplastic anemia | 5 (26.3) | 2 (16.7) | |
Mucosal damage, no. (%) | 16 (84.2) | 6 (50.0) | 0.041 |
 Oral mucositis | 4 (21.0) | 3 (25.0) | 0.798 |
  Gastroenteritis | 12 (63.2) | 3 (25.0) | 0.038 |
Combined antibiotic therapy, no. (%) | 10 (52.6) | 9 (75.0) | 0.213 |
Repeated admission, no. (%) | 13 (68.4) | 10 (83.3) | 0.335 |
Central venous catheter, no. (%) | 11 (57.9) | 10 (83.3) | 0.140 |
Admission to ICU within 60-day, no. (%) | 16 (84.2) | 9 (75.0) | 0.527 |
Neutropenia duration ≥ 7 days, no. (%) | 18 (94.7) | 12 (100.0) | 0.419 |
Status of acute leukemia | Â | Â | Â |
 Completed remission, no. (%) | 8 (42.1) | 4 (33.3) | 0.408 |
  Relapse, no. (%) | 5 (35.7) | 6 (60.0) | 0.239 |